Clinical Trial Results:
Otilonium Bromide in Irritable Bowel Syndrome – (OBIS)
Double blind, randomized, parallel group, placebo-controlled study to evaluate the effect of otilonium bromide on abdominal pain and quality of life in patients with irritable bowel syndrome
Barostat sub-study:
Effect of otilonium bromide versus placebo on the perception of rectal distension in patients with irritable bowel syndrome (IBS).
Summary
|
|
EudraCT number |
2005-001655-38 |
Trial protocol |
BE PT DE ES |
Global completion date |
21 Nov 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
26 Mar 2016
|
First version publication date |
26 Mar 2016
|
Other versions |
|
Summary report(s) |
Synopsis of CSR |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.